Diagnostic agent for tumor
AssigneeSBI Pharmaceuticals Co., Ltd.
InventorsTohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe, Masahiro Ishizuka, Urara Ota
Life of this patent
Estimating the term…
Loading patent…
AssigneeSBI Pharmaceuticals Co., Ltd.
InventorsTohru Tanaka, Kiwamu Takahashi, Motowo Nakajima, Fuminori Abe, Masahiro Ishizuka, Urara Ota
Estimating the term…
It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight.
-8. (canceled)
A method for diagnosing a tumor comprising the following steps (a) and (b);
Dependencies are inferred from the claim text.